Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.35 |
| ▸ | HTR3A | P46098 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671711 | 1.00 | HTR1B (0.38) | HTR1BCHRNA7HTR3ADYRK1AHTR3E | |
| SCHEMBL4670935 | 1.00 | HTR1B (0.38) | HTR1BCHRNA7HTR3ADYRK1AHTR3E | |
| SCHEMBL12749946 | 0.86 | HTR1B (0.38) | HTR1BCHRNA7HTR3ADYRK1AHTR3E | |
| SCHEMBL6670562 | 0.83 | HTR1B (0.36) | HTR1BCHRNA7HTR3ADYRK1AHTR3E | |
| SCHEMBL6666042 | 0.77 | HTR1B (0.38) | HTR1BCHRNA7HTR3ADYRK1AHTR3E | |
| SCHEMBL6664622 | 0.72 | DYRK1A (0.36) | DYRK1A | |
| SCHEMBL13073512 | 0.72 | CYP2A6 (0.47) | HTR1BCHRNA7HTR3ADYRK1AHTR3E | |
| SCHEMBL12749944 | 0.71 | HTR1B (0.38) | HTR1BDYRK1AS1PR1S1PR3CDK9 | |
| SCHEMBL11073058 | 0.71 | HTR1B (0.42) | HTR1BCHRNA7HTR3ADYRK1ACDK9 | |
| SCHEMBL6638354 | 0.71 | CYP1A2 (0.50) | HTR3AS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1116795-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE PYRIDINEETHANOL DERIVATIVES | KANEKA CORP (JP) | 2008-03-12 | — | — | EP | claimed |
| US-7329518-B2 | Enzyme for producing optically active pyridineethanol derivatives | KANEKA CORPORATION (JP) | 2008-02-12 | — | — | US | claimed |
| US-20040043460-A1 | Process for producing optically active pyridineethanol derivatives | KANEKA CORPORATION (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1116795-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE PYRIDINEETHANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2001-07-18 | — | — | EP | claimed |
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-1116795-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE PYRIDINEETHANOL DERIVATIVES | KANEKA CORP (JP) | 2008-03-12 | — | — | EP | disclosed |
| US-7329518-B2 | Enzyme for producing optically active pyridineethanol derivatives | KANEKA CORPORATION (JP) | 2008-02-12 | — | — | US | disclosed |
| EP-0824524-B1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | UPJOHN CO (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20010031871-A1 | Method for producing pyridine derivatives | KURARAY CO., LTD. (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6265580-B1 | REACTING AMINE DERIVATIVE WITH CARBONYLATING AGENT AND NITRILE DERIVATIVE | KURARAY CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1116795-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE PYRIDINEETHANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-6111111-A | Intermediates for producing pyridine derivatives | KURARAY CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| US-6043248-A | VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0911335-A2 | Method for producing furopyridine derivatives and intermediate compounds | KURARAY CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | HTR1B 2052/4885CHRNA7 732/4885HTR3A 3100/4885 |
| US-20010031871-A1 | Method for producing pyridine derivatives | CYP2E1, CBR1, CBR3 | HTR1B 1591/4885CHRNA7 342/4885HTR3A 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.